Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group

about

Gemtuzumab ozogamicin in acute myeloid leukemia.The development of targeted new agents to improve the outcome for children with leukemia.Targeting FLT3 Signaling in Childhood Acute Myeloid Leukemia.Advances in immunotherapy for pediatric acute myeloid leukemia.

P2860

Q38728718-884A3E54-8BB2-42B8-B757-1764939C6D3B Q38964974-1F634AFA-0189-4B6C-9C1D-CBE76183C43D Q47150923-ECAB08A9-05A9-4179-93DA-1901E9DB2271 Q47930962-6A813EA3-0200-4C82-B87A-57F712E0D627

P2860

Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Item

http://www.wikidata.org/entity/Q36805474

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Gemtuzumab Ozogamicin Reduces ...... the Children's Oncology Group

@ast

Gemtuzumab Ozogamicin Reduces ...... the Children's Oncology Group

@en

type

Item

label

Gemtuzumab Ozogamicin Reduces ...... the Children's Oncology Group

@ast

Gemtuzumab Ozogamicin Reduces ...... the Children's Oncology Group

@en

prefLabel

Gemtuzumab Ozogamicin Reduces ...... the Children's Oncology Group

@ast

Gemtuzumab Ozogamicin Reduces ...... the Children's Oncology Group

@en

P1476

Gemtuzumab Ozogamicin Reduces ...... the Children's Oncology Group

@en

P2093

Alan S Gamis

http://www.w3.org/2001/XMLSchema#string

Betsy A Hirsch

http://www.w3.org/2001/XMLSchema#string

Jessica A Pollard

http://www.w3.org/2001/XMLSchema#string

Katherine Tarlock

http://www.w3.org/2001/XMLSchema#string

Lillian Sung

http://www.w3.org/2001/XMLSchema#string

Michael R Loken

http://www.w3.org/2001/XMLSchema#string

Richard Aplenc

http://www.w3.org/2001/XMLSchema#string

Robert B Gerbing

http://www.w3.org/2001/XMLSchema#string

Soheil Meshinchi

http://www.w3.org/2001/XMLSchema#string

Susana C Raimondi

http://www.w3.org/2001/XMLSchema#string

P2860

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.

Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia.

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.

Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial.

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.

P304

1951-1957

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-15-1349

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26644412

http://www.w3.org/2001/XMLSchema#string

P932

4834220

http://www.w3.org/2001/XMLSchema#string

Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group

about

P2860

P2860

Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932